What it is

A dual-receptor research compound activating both GIP and GLP-1 receptors — one of the most-studied molecules in modern metabolic science.

Why it's studied

GLP-2-TZ is the first dual-incretin receptor agonist to reach late-stage research. Activating both arms of the incretin axis in parallel produces effects on metabolic markers that single-pathway compounds don't reach, which is why it's become the new baseline reference in the category.

Key research findings

• Significant reductions in HbA1c documented across late-stage clinical research

• Improvements in lipid profile and blood pressure markers in metabolic studies

• Dual-receptor mechanism distinguishes it from earlier single-pathway research compounds